Sclerostin

Synonyms

Sclerostin, UNQ2976/PRO7455/PRO7476, SOST, Sclerosteosis, DAND6, SOST1, VBCH, CDD

Description

Sclerostin is the negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation.

KO Status

RenMab: F2 (-/-)

Drug Information

Launched drug: 1
Drugs in clinical trials: 3
Latest Research Phase: Approved

Drug Name

Code

Phase

Company

Indications

Clinical Trials

Romosozumab

AMG-785, CDP-7851

Approved

Amgen Inc, Ucb Sa

Osteoporosis, Bone Diseases, Metabolic, Osteoporosis, Postmenopausal, Osteogenesis Imperfecta, Fractures, Bone

Setrusumab

NOV-3, BPS-804, MOR-05813

Phase 2 Clinical

Morphosys, Novartis Pharma Ag

Osteoporosis, Bone Diseases, Metabolic, Hypophosphatasia, Osteogenesis Imperfecta, Renal Insufficiency, Chronic

Blosozumab

LY-2541546, TST002, TST-002

Phase 2 Clinical

Eli Lilly And Company

Osteoporosis, Osteoporosis, Postmenopausal

SHR-1222

SHR-1222

Phase 1 Clinical

Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd

Osteoporosis, Osteoporosis, Postmenopausal

AMG-167

AMG-167

Pending

Amgen Inc

Bone Diseases, Metabolic, Osteoporosis

References


Title

Authors

Source

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

Balemans W., Ebeling M., Patel N., van Hul E., Olson P., Dioszegi M., Lacza C., Wuyts W., van den Ende J., Willems P., Paes-Alves A.F., Hill S., Bueno M., Ramos F.J., Tacconi P., Dikkers F.G., Stratakis C., Lindpaintner K., Van Hul W.,

Hum. Mol. Genet. 10:537-543(2001)

Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein

Brunkow M.E., Gardner J.C., Van Ness J., Paeper B.W., Kovacevich B.R., Proll S., Skonier J.E., Zhao L., Sabo P.J., Fu Y.H., Alisch R.S., Gillett L., Colbert T., Tacconi P., Galas D., Hamersma H., Beighton P., Mulligan J.T.,

Am. J. Hum. Genet. 68:577-589(2001)

The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment

Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J., Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P., Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Gray A.M.,

Genome Res. 13:2265-2270(2003)

DNA sequence of human chromosome 17 and analysis of rearrangement in the human lineage

Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R., Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A., Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J., Chang J.L., Nusbaum C.,

Nature 440:1045-1049(2006)

The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC)

The MGC Project Team,

Genome Res. 14:2121-2127(2004)

Signal peptide prediction based on analysis of experimentally verified cleavage sites

Zhang Z., Henzel W.J.,

Protein Sci. 13:2819-2824(2004)

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., Dioszegi M., Dikkers F.G., Hildering P., Willems P.J., Verheij J.B., Lindpaintner K., Vickery B., Foernzler D., Van Hul W.,

J. Med. Genet. 39:91-97(2002)

SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor

Semenov M., Tamai K., He X.,

J. Biol. Chem. 280:26770-26775(2005)

Proteomics characterization of extracellular space components in the human aorta

Didangelos A., Yin X., Mandal K., Baumert M., Jahangiri M., Mayr M.,

Mol. Cell. Proteomics 9:2048-2062(2010)

Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia

Kim S.J., Bieganski T., Sohn Y.B., Kozlowski K., Semenov M., Okamoto N., Kim C.H., Ko A.R., Ahn G.H., Choi Y.L., Park S.W., Ki C.S., Kim O.H., Nishimura G., Unger S., Superti-Furga A., Jin D.K.,

Hum. Genet. 129:497-502(2011)